Company intelligence / Profile preview

Quest PharmaTech Inc.

Edmonton, Alberta, Canadaquestpharmatech.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Quest PharmaTech is developing Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. The company is also developing Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications, currently in preclinical stage.

Therapeutic areas: OncologyDermatology
Modalities: Monoclonal antibodySmall molecule drug
Industry: Biotech

Drug pipeline

7 assets

leteprinim potassium

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Quest PharmaTech Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quest PharmaTech Inc..

Explore the full profile